Research

LIke ThisLIke ThisLIke This

Program in Cellular and Molecular Medicine (PCMM)

The Program in Cellular and Molecular Medicine (PCMM), previously known as the Immune Disease Institute (IDI), is a research program at Boston Children's Hospital (BCH) recognized worldwide for its discoveries that increase the body's ability to fight disease and to heal.

The breakthroughs of PCMM scientists are greatly increasing our understanding of the influence of immune defense and inflammation on medical discovery, healthcare, and disease management.

PCMM officially joined seven other interdisciplinary programs at Boston Children's Hospital in October 2012 with the goal of increasing collaborations and scientific synergies.

Our investigators are academically affiliated with Harvard Medical School.


Featured News Story



January 3, 2017

Dr. Hidde Ploegh Joins PCMM

HiddePloeghThe Program in Cellular and Molecular Medicine (PCMM) would like to welcome Dr. Hidde Ploegh who has joined the Department of Medicine at Boston Children's Hospital as of December 2016.   Pending completion of his appointment to Harvard Medical School, Dr. Ploegh, who is a former PCMM Scientific Advisory Board member, has been nominated to become a PCMM Investigator and also has been nominated to serve as the first incumbent of a Professorship newly endowed by G.D. Yancopoulos in honor of Frederick W. Alt at Boston Children’s Hospital and Harvard Medical School.   

Prior to joining PCMM, Dr. Ploegh was a Professor of Biology at MIT since 2005. Dr. Ploegh is a world-renowned immunologist, cell biologist, and biochemist, who has won many awards for his research. Most recently, Dr. Ploegh was elected as a member of the United States National Academy of Sciences.  His research focuses on molecular immunology, particularly the cell biology and biochemistry of surface proteins relevant for immune recognition. His long-term goal is to establish improved tools to explore the immune response non-invasively and to develop approaches for therapeutic interventions, guided by experiments in the appropriate mouse models.  In the last few years, Dr. Ploegh has broadened his research interests to include tumor immunology and immuno-PET to track the impact of antibody-based therapies that target immune checkpoints such as PD-L1.  His current laboratory is located on the 6th floor of the Karp building.

 
December 22, 2016

UTX makes NKTUTX

Published in Nature Immunology this week, the Winau lab in collaboration with Stuart Orkin's group investigated the impact of histone methylation on leukocyte development and found an exclusive effect of histone H3-lysine 27 (H3K27) demethylase UTX on thymic development of invariant natural killer T (iNKT) cells.

Read More.

 
October 25, 2016

Modulation of Scramblase: a novel paradigm to fight chronic infection and cancerScramblase

In a study published in The Journal of Experimental Medicine, the Winau lab identified a new pathway involving scramblase TMEM16F that preserves efficient T cell responses to control viral infection. These findings provide a novel target for therapy against chronic diseases such as cancer, as well as HIV and hepatitis B virus infections.


Read More.
 


LIke ThisLIke ThisLIke This
Close